Aptalis Pharmaceutical Technologies Expands Licensing Team
Nigel Ray to lead Global Development and Licensing Efforts
Bridgewater, New Jersey, February 13, 2013 –Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that develops differentiated products utilizing its oral delivery technologies, today announces that Nigel Ray has been named as the company's Vice President of Global Licensing. Reporting to John Fraher, President of Aptalis Pharma, Mr. Ray will lead the unit's global licensing efforts as well as the identification and evaluation of strategic opportunities within the pharmaceutical industry that maximize the value of Aptalis' technologies. Prior to joining Aptalis, during his twenty-five years in specialty pharmaceuticals, Mr. Ray held executive-level positions with companies including AcelRx Pharmaceuticals, DURECT Corporation and Alza Corporation. Mr. Ray holds a Bachelor of Arts in Human Biology from Stanford University and a Master of Business Administration, Finance and Strategy from the UCLA Anderson School of Management.
"Nigel's rich experience in identifying, structuring and negotiating complex, worldwide product licensing transactions, as well as his business leadership skills, will serve Aptalis well," said Mr. Fraher. "His leadership and experience in business development and marketing will enable the expansion of our technology partnerships while providing pharmaceutical companies with the drug delivery solutions they need to advance and protect product portfolios," added Mr. Fraher.
About Aptalis Pharmaceutical Technologies
Aptalis Pharmaceutical Technologies offers a broad portfolio of oral drug delivery technology platforms: Customized Drug Release, Bioavailability Enhancement, and Taste Masking for ODT's (orally disintegrating tablets) and other dosage forms. Together, these technology platforms combined with best in class R&D, formulation development and manufacturing capabilities enable Aptalis Pharmaceutical Technologies to produce customized drug formulation solutions for partners across a range of dosage forms and therapies with high patient acceptability. Aptalis Pharmaceutical Technologies develops and manufactures products, both for itself and for partners, as well as support the drug development process for the Aptalis Pharma pipeline and portfolio of products. For more information about Aptalis Pharmaceutical Technologies, visit www.AptalisPharmaTech.com
About Aptalis
Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®, RECTIV®, VIOKACE™, ULTRESA™, LACTEOL®, DELURSAN®, PANZYTRAT®, and SALOFALK®. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.aptalispharma.com.
.
# # #
Media Contact:
Erin O'Brien, Director of Marketing
Aptalis Pharmaceutical Technologies
908-927-9600, Ext. 4084
[email protected]